Despite advances in prophylaxis and therapy, infections remain a major source of morbidity and mortality after lung transplantation. Lung transplant recipients are at increased risk for both community-acquired and nosocomial pathogens, which may develop at various time points. The risk of infections increases with the intensity of immunosuppression. Careful assessment of the recipient is essential to assure adequate prophylactic or preemptive therapy. Aggressive prophylaxis for some infections (e.g., cytomegalovirus) has substantially reduced the prevalence of serious infections due to this organism. Tuberculin-positive individuals should be treated with prophylactic isoniazid to reduce the chance for reactivation of tuberculosis following transplantation. Myriad opportunistic pathogens (including various viruses, bacteria, fungi, etc.) may complicate transplantation, owing to the effects of multiagent immunosuppressive therapy. This review addresses the salient pathogens that may infect organ transplant recipients, and discusses strategies to prevent or treat specific pathogens in this highly susceptible patient population.
1
The risk for particular infections is related to host and environmental factors. Effective prevention requires an understanding of patient risk factors, including time posttransplant and net host immunosuppression as well as utilization of serological and molecular tools for early diagnosis. Pretransplant screening of donor and recipient affords an opportunity to individualize preventive strategies. In addition to traditionally recognized pathogens, new challenges are posed by antimicrobial resistance and by emerging organisms.
DONOR AND RECIPIENT PRETRANSPLANT SCREENING Both donor and recipient undergo a standard panel of serologic testing (see Table 1 ), 2 which serves several purposes: to define risk more precisely, to guide preand posttransplant interventions, and occasionally to disqualify donor or recipient (Table 2) . 3 For example, a donor positive for human immunodeficiency virus (HIV) antibody or hepatitis B surface antigen (HBsAgþ) generally would not be used. On the other hand, a hepatitis B core-positive donor (HBcAb þ , HBsAgÀ) could be used with appropriate prophylaxis and monitoring (see later discussion). [4] [5] [6] High risk status such as cytomegalovirus (CMV) donor seropositive, recipient seronegative (Dþ/RÀ) status might influence the choice of posttransplant prophylaxis and monitoring for CMV.
A thorough history and physical examination are performed on transplant candidates to detect any past infections that may have been untreated or only partially treated. Latent tuberculosis infection is particularly important because of the devastating effects of TB reactivation posttransplant. 7 Every candidate should have a purified protein derivative (PPD) performed and those with positive PPDs should receive isoniazid prophylaxis if not previously administered. Attention should be paid to potential exposures to geographic diseases. For example, candidates from the southwestern United States should be screened for coccidioidomycosis, although false-positive immunoglobulin (Ig)M tests may occur in cystic fibrosis (CF) patients. 8 Patients with history of residence in tropical areas should have a serology for Strongyloides performed to avoid disseminated strongyloidiasis after transplant that is frequently fatal. Serology for Chagas' disease (Trypanosoma cruzi) is appropriate in patients from endemic areas in Latin America.
A history of active fungal or mycobacterial infection is important. The dates and doses of therapy should be recorded as well as radiographic and clinical responses. In some cases, when the active infection has been controlled, therapy that has been initiated pretransplant can be completed posttransplant. Active infection and colonization can be difficult to distinguish, particularly in the case of fungal infection. Cultures for bacterial organisms colonizing the recipient, including full antimicrobial sensitivity panels, should be obtained and this information utilized to design the initial peritransplant antimicrobial regimen. These cultures are particularly important in patients with cystic fibrosis who are often colonized with multiresistant Pseudomonas aeruginosa, methicillinresistant Staphylococcus aureus (MRSA), Stenotrophomonas maltophilia, and others. The finding of Burkholderia cepacia, particularly genomovar 3, will disqualify the patient from transplantation at some centers (see later discussion).
The pretransplant phase is an excellent time to update the immunization status of the recipient because vaccinations will be more effective when administered prior to the onset of transplant immunosuppression. 3, 9 The pneumococcal vaccine should be administered if it has not been given within 5 years. Tetanus-diphtheriapertussis boosters and yearly influenza vaccine are important. A varicella-seronegative patient is at high risk if primary varicella develops posttransplant and therefore the live attenuated varicella vaccine should be considered (but not if the patient is expected to be transplanted within 3 weeks). Hepatitis B immunization is important in that a hepatitis B core-positive donor may be offered, which would be safer if transplanted into an immune recipient. 4 Because responses to the standard three-dose HBV (hepatitis B virus) vaccine series may be suboptimal in patients with advanced disease, accelerated or enhanced-potency regimens have been advocated. 10 On the day of transplant, cultures from the recipient and donor tissue are often sent for bacterial, fungal, and acid-fast stains and cultures. In addition, blood cultures are recommended on any donor hospitalized for 72 hours or more. 2 Initial results from these cultures may not be available until 2 to 3 days posttransplant but are helpful in guiding therapy. A recent study showed that donor lower airway colonization in general is associated with poorer outcomes. 11 Little information is available on the optimal length of culture-based therapy in this setting, but donor lung cultures with virulent organisms such as MRSA should prompt consideration of longer therapy in the recipient.
GENERAL PRINCIPLES: THE NET STATE OF IMMUNOSUPPRESSION
The concept of the ''net state of immunosuppression,'' coined by Rubin, denotes a constellation of factors that contribute to risk for infections in a particular transplant recipient. 1 These factors include not only 
INFECTIONS AFTER LT/AVERY
immunosuppressive medications but also the underlying disease for which the transplant was performed; age; comorbid conditions such as diabetes, renal dysfunction, metabolic and nutritional factors; breakdown of skin and mucosal barriers; leukopenia; and immunomodulatory effects of infections themselves. At any given time, the risk for infection depends on both the patient's net state of immunosuppression and environmental exposures (e.g., to Aspergillus from a construction site; Cryptococcus from bird droppings; nosocomial intensive care unit (ICU) bacterial pathogens; or community-acquired respiratory viruses). 1 Increasing interest has focused on measures of host immunity, either globally or in response to specific pathogens.
An understanding of the net state of immunosuppression can lead to interventions for infection prevention. Doses of immunosuppressive agents can be modulated, for example, in response to the absolute lymphocyte count as well as drug levels. Posttransplant hypogammaglobulinemia has been found to occur in one third of patients and represents a potentially modifiable risk factor for bacterial and fungal infections posttransplant. 12 
THE EPIDEMIOLOGY OF INFECTIONS AS A FUNCTION OF TIME POST TRANSPLANT
Under the paradigm proposed by Rubin, there are three major time periods after transplant. 1 During the first month, infections are most commonly those that can be seen in any postoperative setting: catheter-related, wound, pneumonia, and urinary tract. In lung recipients, special considerations include the influence of donorand recipient-colonizing organisms, the potential for mechanical complications such as hemothorax and empyema, and anastomotic complications that are frequently associated with infection.
In the second period, approximately from month 2 to 6 posttransplant, opportunistic infections emerge, including CMV, Epstein-Barr virus-related posttransplant lymphoproliferative disease (EBV-PTLD), fungal infections, nocardiosis, and Pneumocystis carinii pneumonia (PCP). It is this time period in which prophylaxis and monitoring are most intensified. The extent to which infections occur during this period also varies with the nature and duration of specific antimicrobial prophylaxis employed after transplant. For example, prolonged CMV prophylaxis might delay the onset of infection until the next period.
In the late period from 6 months on, some patients who have done well with allograft function and minimal immunosuppression may have relatively fewer opportunistic infections, though still subject to community-acquired respiratory viruses and bacterial pneumonias. However, others who have developed bronchiolitis obliterans syndrome (BOS) and/or are still receiving high levels of immunosuppression continue to be subject to opportunistic pathogens and may have multiple recurrent infections or refractory courses.
BACTERIAL INFECTIONS, INCLUDING MULTIRESISTANT BACTERIA
Bacterial infections may relate to preexisting colonization of recipient or donor, complications of the transplant operation, nosocomial exposure, or communityacquired infection. In one series, bacterial infections constituted two thirds of infectious complications in lung transplant recipients, and many of these were due to gram-negative organisms. 13 CF patients are often colonized with multiresistant Pseudomonas aeruginosa; however, such colonization is not considered a contraindication to transplant. 14, 15 Despite posttransplant prophylaxis, Pseudomonas pneumonia may develop either early or late posttransplant, or may occur de novo in non-CF recipients; however, early posttransplant pseudomonal infection is most common in CF. 16 Available antipseudomonal antibiotics represent relatively few drug categories. The enhanced risk of nephrotoxicity of systemic aminoglycosides in the setting of calcineurin inhibitors further limits the choice of drugs. Combination therapy with inhaled tobramycin or colistin is common but many patients have already received these drugs pretransplant. It has been suggested that pretransplant use of aerosolized colistin may decrease resistance of the pseudomonal isolate. 17 New drug development and newer strategies to reduce pseudomonal infection are an important area for future research. Synergy testing on apparent panresistant isolates may sometimes yield therapeutic options. 18 The macrolide drug azithromycin appears to have beneficial effects both in patients with CF 19 and in transplant recipients with BOS. 20 Mechanisms are still being clarified but appear to include reduction in inflammatory processes, 21 and interference with the synthesis of Pseudomonas virulence factors. 22 Pretransplant colonization with Burkholderia cepacia in CF appears to be a risk factor for poor posttransplant outcome. 23 De novo acquisition of B. cepacia after transplant is also associated with high mortality. 23 The work of LiPuma and others has identified genomovar 3 as being particularly associated with poor survival. [24] [25] [26] At some centers, B. cepacia colonization, particularly genomovar 3, is considered a contraindication to transplantation given the high risk for posttransplant death due to recurrent B. cepacia infection. If transplant is considered in patients with B. cepacia aggressive use of multiple antibiotics with activity against this pathogen seems prudent. In addition, MRSA and Stenotrophomonas are increasingly common pretransplant colonizers, especially in CF patients. Strategies for infection control among CF patients are important to prevent person to person spread of these and other multiresistant bacteria. 27 Bacterial infections may also be acquired as a consequence of early posttransplant mechanical complications. Pleural complications after transplant occurred in 22% of recipients in one series and were associated with empyema in about one quarter of these. 28 A more recent series identified empyema in 3.6% of 392 recipients 29 32, 33 Metal stents have been increasingly utilized to manage airway complications [33] [34] [35] ; although these stents may become colonized with organisms, in one study the incidence of infection was reduced after stents came into use. 35 Nosocomial bacterial infections are a concern both in the immediate pretransplant period and in subsequent hospitalizations. Increasingly resistant isolates include MRSA, extended-spectrum b-lactamase producing Escherichia coli and Klebsiella, and multiresistant Pseudomonas, Acinetobacter, and Stenotrophomonas. Meticulous infection control practices, avoidance of technical complications, and judicious use of antibiotics are important in preventing these infections. Clostridium difficile incidence and virulence have risen recently, with increased numbers of colectomies and deaths. Immunocompromised patients are particularly susceptible to C. difficile complications. C. difficile may present with leukocytosis and abdominal distention with or without diarrhea; megacolon or perforation may ensue and should be considered in the differential diagnosis of an acute abdomen in a hospitalized transplant patient. 36 Legionellosis can occur in either nosocomial or community settings. Legionella pneumophila and other less common legionellae can cause a variety of syndromes, including a rapidly progressive, multilobar pneumonia with respiratory failure. The diagnosis may be difficult, especially when other concomitant infections are present. 37 Hospital water systems are recognized reservoirs for Legionella transmission, and surveillance cultures have been recommended. 38, 39 Pneumococcal pneumonia is one of the most important community-acquired bacterial infections. In one series, invasive pneumococcal infection occurred in 6.4% of lung transplant recipients at a median of 1.3 years posttransplant. 40 Most were serotypes from the 23-valent vaccine and many were resistant to trimethoprim-sulfamethoxazole, which patients were receiving for PCP prophylaxis. 40 The use of the conjugated pneumococcal vaccine for enhanced immunogenicity in pretransplant recipients is an area of active research.
Chlamydia pneumoniae and Mycoplasma pneumoniae are common community-acquired respiratory pathogens that usually cause relatively mild syndromes in immunocompetent individuals. However, in lung transplant recipients, C. pneumoniae has been found by polymerase chain reaction in 25% of patients within 30 days of lung transplantation and is associated with poorer survival, rejection, and bronchiolitis obliterans. 41 It is possible that the increasing use of prophylactic azithromycin may ameliorate this complication.
Another bacterial infection seen in lung transplant recipients is nocardiosis. Nocardia spp. are filamentous, beaded, branching gram-positive bacteria that are found in the external environment. Nocardia spp. most commonly infect the lungs, causing nodular infiltrates and sometimes cavitation, but also can involve the brain, bone and joint, skin and soft tissues, and other areas. Husain et al identified nocardiosis in 2.1% of lung recipients at a median time of $3 years posttransplant. 42 Posttransplant diabetes was present in half of these patients; in single-lung recipients, nocardiosis usually involved the native lung. 42 Prophylaxis with trimethoprim-sulfamethoxazole was not completely protective. 42 Listeriosis is a foodborne bacterial infection that causes bacteremia and meningitis in immunocompromised patients. Soft cheeses, unpasteurized dairy foods, frankfurters, and other foods have been implicated in its spread. Transplant recipients should be advised to avoid these foods and to heat all leftovers to steaming hot because Listeria can survive at refrigerator temperature. An unusual case of early posttransplant Listeria pleural infection has been reported. 43 Mycobacterial infections, both tuberculous (TB) and nontuberculous, can occur, usually as a result of reactivation within the recipient. As already discussed, all recipients should be screened with a PPD pretransplant and should be strongly considered for prophylaxis if they have not previously received it. Posttransplant active TB carries a high mortality, and treatment is difficult because rifampin sharply decreases levels of calcineurin inhibitors. Nontuberculous mycobacterial infections include Mycobacterium avium complex and the rapid growers, M. fortuitum, M. chelonae, and M. abscessus. These may present with nodular pulmonary infiltrates with or without systemic symptoms, and typically require combinations of several drugs for long periods of time. Tolerability of the treatment regimen is an issue, as are drug interactions (rifampin and rifabutin drop, and clarithromycin raises, calcineurin inhibitor levels). If a macrolide is to be included in the regimen, azithromycin is preferred.
FUNGAL INFECTIONS: CANDIDA, ASPERGILLUS, CRYPTOCOCCUS, ENDEMIC MYCOSES, AND EMERGING FUNGI Fungal infections after transplantation also occur in relation to preexisting colonization or latency, to mechanical airway complications, and to environmental exposures. 44 Candidal infections are most commonly associated with airway anastomotic complications. 32, 45 These infections may be symptomatic with dyspnea or may be discovered on surveillance bronchoscopy. Combinations of inhaled and systemic antifungal agents have been recommended. 45 Aspergillus infections are of several varieties. [46] [47] [48] [49] Invasive infection is the most feared complication and carries a high mortality. More commonly, however, Aspergillus growing in sputum or bronchoalveolar lavage (BAL) cultures represents colonization. Although colonization is a risk factor for invasive disease, only a fraction of colonized patients go on to develop more serious infections. Criteria for preemptive or therapeutic use of antifungal agents have varied from center to center. 46 Lung recipients appear particularly susceptible to endobronchial forms of fungal infection. Airway and anastomotic infections with Aspergillus have been well described, [47] [48] [49] including ulcerative tracheobronchitis. In one recent series, single-lung transplant recipients with bronchial anastomotic infection had a reduced 5 year survival. 47 In this series, late-onset aspergillosis in conjunction with chronic allograft dysfunction was also a risk factor for poorer survival. 47 Prevention of aspergillosis involves infection-control measures such as wearing masks while traversing areas of hospital construction, as well as avoiding gardening, compost, and other outdoor exposures. Universal prophylaxis is utilized at some centers, whereas others choose preemptive therapy based on surveillance bronchoscopic cultures, but randomized multicenter data would be helpful. 46 Agents used for prophylaxis have included inhaled amphotericin B, 50 liposomal amphotericin, 51 itraconazole, 52 voriconazole, and others. At one center, itraconazole prophylaxis reduced the attack rate of invasive aspergillosis in lung transplant patients from 12.8 to 4.9%. 52 Treatment of pretransplant Aspergillus colonization has not been shown to reduce incidence of posttransplant aspergillosis, but invasive aspergillosis pretransplant should be fully treated prior to transplantation. The complex issues in design of clinical trials in antifungal prophylaxis have been well summarized by Singh. 53 Cryptococcosis may be localized to lungs, central nervous system, skin, or other sites. Cryptococcus is associated with pigeon and other bird exposures. It appears to be less common in lung than in heart and small bowel transplant recipients. 54 Histoplasmosis, blastomycosis, and coccidioidomycosis are geographically limited fungal infections. Coccidioidomycosis occurs in the southwestern United States and Mexico. Donor transmission of coccidioidomycosis has resulted in cases of early fulminant pneumonia and dissemination. 55, 56 Histoplasmosis is common in the U.S. Midwest and can reactivate in disseminated form posttransplant, often as a fever of unknown origin with pancytopenia.
Perhaps most concerning is the emergence of newer fungal pathogens in recent years, many with resistance to standard antifungal drugs. 57, 58 Organisms such as Scedosporium (Pseudallescheria), 57 Paecilomyces, Fusarium, and others are a diagnostic and therapeutic challenge. Microbiological identification is important because some species resemble each other on histopathology but may have vastly different profiles of susceptibility to antifungal agents.
Pneumocystis jiroveci (formerly carinii), once classified as a parasite, is now thought to be closer to the fungi. Pneumocystis can cause a devastating, diffuse pneumonia (PCP) with respiratory failure. Universal prophylaxis with trimethoprim-sulfamethoxazole has become standard, but centers differ in their duration of prophylaxis. In a study of late PCP, Gordon et al 58a found that, in lung recipients, in contrast to other organ transplant recipients, the incidence of PCP did not decrease after the first year, and they recommended lifelong prophylaxis. For sulfa-allergic patients, aerosolized pentamidine, dapsone, or atovaquone are options; dapsone requires a G6PD screen.
VIRAL INFECTIONS, INCLUDING CMV, EBV, AND COMMUNITY RESPIRATORY VIRUSES
A huge amount of research has addressed the issue of viral infections after lung transplant, especially CMV. In the early years of lung transplantation, CMV pneumonitis was common 59 ; it was identified in several studies as a risk factor for later BOS. [60] [61] [62] In the prophylaxis era, with reductions in symptomatic CMV and earlier treatment, it has been more difficult to demonstrate a link with BOS. 63, 64 Interestingly, in a recent study by Neurohr and colleagues in which viral PCR assays were performed on BAL fluid, it was not CMV but human herpesvirus-6 (HHV-6) that was most strongly associated with BOS. 65 Nonetheless, prevention of CMV remains a significant challenge. Ganciclovir-resistant CMV also occurs in lung recipients, particularly those with high risk Dþ/RÀ status, even in those who have received preemptive rather than prophylactic antiviral therapy. 66 Prophylactic regimens have involved ganciclovir (IV or oral), 67 valganciclovir, 68, 69 CMV hyperimmune globulin, 69 and combinations of these agents. The optimal regimen and duration are still a matter of debate.
Epstein-Barr virus (EBV) is associated with posttransplant lymphoproliferative disease (PTLD). Approximately 90% of adults are seropositive for EBV. In one series, PTLD developed in 2.5% of lung transplant recipients; the lung was a frequent site of involvement. 70 In past, the prognosis of PTLD was disappointing; however, newer therapies such as rituximab appear to have improved the outlook significantly. 70 EBV seronegative recipients with seropositive donors, and those who have received augmented immunosuppression (especially with antilymphocyte therapy), appear to be at particular risk. The value of monitoring the EBV viral load with either or both preemptive reduction of immunosuppression and antiviral therapy is an area of current research. 71 Whereas there is still debate on the effects of CMV on the allograft, there is considerable evidence that community-acquired respiratory viruses such as influenza, parainfluenza, adenovirus, and respiratory syncytial virus have adverse long-term effects on lung function. [72] [73] [74] [75] [76] Kumar et al found that rhinovirus and coronavirus, ''common cold'' viruses, were also deleterious in this regard. 77 Gerna et al identified human metapneumovirus as an important lower respiratory tract pathogen. 78 Prevention of these infections involves stringent infection control practices in hospitalized patients; influenza vaccinations for health care workers and family members as well as patients; oseltamivir preemptive therapy for influenza-exposed transplant recipients; and possibly aerosolized ribavirin therapy for RSV (respiratory syncytial virus) infection, though practice varies.
Viral hepatitis can derive either from the donor or from the recipient. Shitrit et al reported on four HBsAgþ recipients who received posttransplant lamivudine, which was effective except in one recipient who required adefovir. 6 As already mentioned, HBsAg þ donors are generally not used, but HBcAbþ, HBsAgÀ donors represent a low risk for transmission, 4 especially into a vaccinated recipient or with lamivudine prophylaxis. 6 Hepatitis C, on the other hand, is much more likely to be transmitted from donors in thoracic transplantation. 4, 79 A survey of practices of lung transplant centers showed that 72% of centers consider HCV-positive candidates for transplant, and 55% use HCVþ donors, many for HCVþ recipients. 80 Emerging infections such as West Nile virus and sudden acute respiratory syndrome (SARS) may affect the transplant recipient more severely. 81, 82 The specter of a possible influenza pandemic and avian influenza is very concerning, yet there are concrete measures that can protect transplant recipients as well as others through rational planning. 83 Cooperation between experts in infectious disease, transplantation, epidemiology, and public policy will be needed.
CONCLUSION
Lung transplant recipients are susceptible to a wide range of different infections. Some derive from preexisting colonization in the donor or recipient; some are acquired through nosocomial or environmental exposures, and some relate to mechanical complications of the transplant. Prophylaxis, monitoring, and judicious immunosuppression have ameliorated the incidence and severity of some infections, but new threats are emerging, including antimicrobial-resistant pathogens. The degree to which particular infections cause long-term damage to allograft function is still a matter of active research.
